By Gina Shaw
Next week’s hearing on effective administration of the 340B federal drug pricing program, to be held before the full Senate Health, Education, Labor and Pensions (HELP) Committee on June 19, will likely include pointed questions on the latest delay in implementing the program’s Final Rule, with the main concern focusing on regulations for the program’s ceiling price.
In a Notice of Proposed Rulemaking published in the Federal Register on May 7, the effective date